This highlight demonstrates potential inhibitors of Nav 1.8 voltage-gated sodium channels, suggesting new treatments for pain disorders.
This highlight outlines the development of novel substituted 1-phenyl-2,3-dihydroquinazolin-4(1H)-one derivatives as potential inhibitor candidates for Nav 1.8 voltage-gated sodium channels (Nav 1.8), which is upregulated or activated to transmit nociceptive signaling in a range of pain-related disorders. The invention includes details on preparation methods, biological activity assays, and pharmaceutical compositions.
No takes yet. Share an insight, caveat, or question.
Song et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: